-
1.发明公开USE OF TRANSTHYRETIN PEPTIDE/PROTEIN FUSIONS TO INCREASE THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES/PROTEINS 有权甲状腺素肽/蛋白质的兼并续期血清半衰期药物活性肽/蛋白质的的使用
公开(公告)号：EP1496926A1
公开(公告)日：2005-01-19
申请号：EP03721538.1
申请日：2003-04-03
申请人： Amgen Inc.
发明人： WALKER, Kenneth , XIONG, Fei
IPC分类号： A61K38/00
CPC分类号： C07K14/47 , A61K38/043 , A61K38/10 , A61K38/20 , A61K38/29 , A61K47/58 , A61K47/60 , A61K47/61 , A61K47/643 , C07K2319/31
摘要： The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.
-
公开(公告)号：EP3027642B1
公开(公告)日：2020-08-19
申请号：EP14752711.3
申请日：2014-07-31
申请人： Amgen Inc.
发明人： XIONG, Yumei , ZHANG, Yi , SHENG, Jackie, Z. , HAMBURGER, Agnes, Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN, Gunasekaran , MOCK, Marissa , WALKER, Kenneth
IPC分类号： C07K14/475 , A61P13/12 , A61P3/00
-
公开(公告)号：EP3027642A1
公开(公告)日：2016-06-08
申请号：EP14752711.3
申请日：2014-07-31
申请人： AMGEN, INC.
发明人： XIONG, Yumei , ZHANG, Yi , SHENG, Jackie, Z. , HAMBURGER, Agnes, Eva , VENIANT-ELLISON, Murielle , SHIMAMOTO, Grant , MIN, Xiaoshan , WANG, Zhulun , TANG, Jie , KANNAN, Gunasekaran , MOCK, Marissa , WALKER, Kenneth
IPC分类号： C07K14/495 , C12N15/62
摘要： Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：EP3692061A1
公开(公告)日：2020-08-12
申请号：EP18797214.6
申请日：2018-10-03
申请人： Amgen Inc.
发明人： WALKER, Kenneth
-
5.发明授权USE OF TRANSTHYRETIN PEPTIDE/PROTEIN FUSIONS TO INCREASE THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES/PROTEINS 有权甲状腺素肽/蛋白质的兼并续期血清半衰期药物活性肽/蛋白质的的使用
公开(公告)号：EP1496926B1
公开(公告)日：2012-12-19
申请号：EP03721538.1
申请日：2003-04-03
申请人： AMGEN INC.
发明人： WALKER, Kenneth , XIONG, Fei
CPC分类号： C07K14/47 , A61K38/043 , A61K38/10 , A61K38/20 , A61K38/29 , A61K47/58 , A61K47/60 , A61K47/61 , A61K47/643 , C07K2319/31
-
-
-
-
搜索结果
5 条记录 (耗时 0.015 秒)
